Shigella IpaB and IpaD displayed on L. lactis bacterium-like particles induce protective immunity in adult and infant mice

Immunology and Cell Biology

Volumn 93, Issue 7, 2015, Pages 641-652

  Heine, Shannon J ^a,b   Franco Mahecha, Olga L ^a,b   Chen, Xiaotong ^c   Choudhari, Shyamal ^c   Blackwelder, William C ^a   Van Roosmalen, Maarten L ^d   Leenhouts, Kees ^d   Picking, Wendy L ^c   Pasetti, Marcela F ^a,b  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KANSAS   (United States)

^d Mucosis BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IPAB PROTEIN; IPAD PROTEIN; SHIGELLA VACCINE; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; IMMUNOLOGICAL ADJUVANT; IPAB PROTEIN, SHIGELLA; IPAD PROTEIN, SHIGELLA FLEXNERI; RECOMBINANT VACCINE;

ADOPTIVE TRANSFER; ADULT; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; INFANT; LACTOCOCCUS LACTIS; LUNG LAVAGE; MOUSE; NEWBORN; NONHUMAN; SHIGELLA; SHIGELLOSIS; SURVIVAL RATE; AGING; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BONE MARROW; BRONCHOALVEOLAR LAVAGE FLUID; COMPARATIVE STUDY; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; LUNG; NOSE MUCOSA; VACCINATION;

BACTERIA (MICROORGANISMS); LACTOCOCCUS LACTIS; MUS; SHIGELLA; SHIGELLA FLEXNERI; SHIGELLA SONNEI;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ADOPTIVE TRANSFER; AGING; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BONE MARROW; BRONCHOALVEOLAR LAVAGE FLUID; FEMALE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LACTOCOCCUS LACTIS; LUNG; MICE; MICE, INBRED BALB C; NASAL MUCOSA; SHIGELLA VACCINES; VACCINATION; VACCINES, SYNTHETIC;

EID: 84938966499     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2015.24     Document Type: Article

References (49)

1. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, casecontrol study. Lancet 2013; 382: 209-222.
2. Van de Verg LL, Venkatesan MM. A Shigella vaccine against prevalent serotypes. Clin Infect Dis 2014; 59: 942-943.
3. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disabilityadjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2197-2223.
4. Heine SJ, Diaz-McNair J, Martinez-Becerra FJ, Choudhari SP, Clements JD, Picking WL, et al. Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD. Vaccine 2013; 31: 2919-2929.
5. Martinez-Becerra FJ, Kissmann JM, Diaz-McNair J, Choudhari SP, Quick AM, Mellado-Sanchez G, et al. Broadly protective Shigella vaccine based on type III secretion apparatus proteins. Infect Immun 2012; 80: 1222-1231.
6. Heine SJ, Diaz-McNair J, Andar AU, Drachenberg CB, Van D, Walker VR, et al. Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypesJ Immunol 2014; 192: 1630-1640.
7. Martinez-Becerra FJ, Scobey M, Harrison K, Choudhari SP, Quick AM, Joshi SB, et al. Parenteral immunization with IpaB/IpaD protects mice against lethal pulmonary infection by Shigella. Vaccine 2013; 31: 2667-2672.
8. van Roosmalen ML, Kanninga R, El Khattabi M, Neef J, Audouy S, Bosma T, et al. Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria. Methods 2006; 38: 144-149.
9. Bosma T, Kanninga R, Neef J, Audouy SA, van Roosmalen ML, Steen A, et al. Novel surface display system for proteins on non-genetically modified Gram-positive bacteria. Appl Environ Microbiol 2006; 72: 880-889.
10. Ramirez K, Ditamo Y, Rodriguez L, Picking WL, van Roosmalen ML, Leenhouts K, et al. Neonatal mucosal immunization with a non-living, non-genetically modified Lactococcus lactis vaccine carrier induces systemic and local Th1-type immunity and protects against lethal bacterial infection. Mucosal Immunol 2010; 3: 159-171.
11. Keijzer C, Haijema BJ, Meijerhof T, Voorn P, de HA, Leenhouts K, et al. Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion. Vaccine 2014; 32: 2904-2910.
12. Rigter A, Widjaja I, Versantvoort H, Coenjaerts FE, van RM, Leenhouts K, et al. A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles. PLoS ONE 2013; 8: e71072.
13. Nganou-Makamdop K, van Roosmalen ML, Audouy SA, van Gemert GJ, Leenhouts K, Hermsen CC, et al. Bacterium-like particles as multi-epitope delivery platform for Plasmodium berghei circumsporozoite protein induce complete protection against malaria in mice. Malar J 2012; 11: 50.
14. Audouy SA, van Selm S, van Roosmalen ML, Post E, Kanninga R, Neef J, et al. Development of lactococcal GEM-based pneumococcal vaccines. Vaccine 2007; 25: 2497-2506.
15. Saluja V, Amorij JP, van Roosmalen ML, Leenhouts K, Huckriede A, Hinrichs WL, et al. Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant. AAPS J 2010; 12: 109-116.
16. de HA, Haijema BJ, Voorn P, Meijerhof T, van Roosmalen ML, Leenhouts K. Bacteriumlike particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration. Vaccine 2012; 30: 4884-4891.
17. Saluja V, Visser MR, Ter VW, van Roosmalen ML, Leenhouts K, Hinrichs WL, et al. Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles. Vaccine 2010; 28: 7963-7969.
18. Livio S, Strockbine NA, Panchalingam S, Tennant SM, Barry EM, Marohn ME, et al. Shigella isolates from the global enteric multicenter study inform vaccine development. Clin Infect Dis 2014; 59: 933-941.
19. von SL, Kim DR, Ali M, Lee H, Wang X, Thiem VD, et al. A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology. PLoS Med 2006; 3: e353.
20. Toro CS, Farfan M, Contreras I, Flores O, Navarro N, Mora GC, et al. Genetic analysis of antibiotic-resistance determinants in multidrug-resistant Shigella strains isolated from Chilean children. Epidemiol Infect 2005; 133: 81-86.
21. Van Braeckel-Budimir N, Haijema BJ, Leenhouts K. Bacterium-like particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applications. Front Immunol 2013; 4: 282.
22. Leenhouts K. MimopathTM-Based Vaccine Delivery. In: Singh M (ed.). Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines. Springer Science Business Media: New York. 2013, 245-265.
23. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010; 10: 787-796.
24. Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. The function of Fcgamma receptors in dendritic cells and macrophages. Nat Rev Immunol 2014; 14: 94-108.
25. Debarry J, Garn H, Hanuszkiewicz A, Dickgreber N, Blumer N, von ME, et al. Acinetobacter lwoffii and Lactococcus lactis strains isolated from farm cowsheds possess strong allergy-protective properties. J Allergy Clin Immunol 2007; 119: 1514-1521.
26. Cohen D, Green MS, Block C, Rouach T, Ofek I. Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population. J Infect Dis 1988; 157: 1068-1071.
27. Cohen D, Green MS, Block C, Slepon R, Ofek I. Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis. J Clin Microbiol 1991; 29: 386-389.
28. Cohen D, Ashkenazi S, Green MS, Gdalevich M, Robin G, Slepon R, et al. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet 1997; 349: 155-159.
29. Passwell JH, Ashkenzi S, Banet-Levi Y, Ramon-Saraf R, Farzam N, Lerner-Geva L, et al. Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. Vaccine 2010; 28: 2231-2235.
30. Black RE, Levine MM, Clements ML, Losonsky G, Herrington D, Berman S, et al. Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine. J Infect Dis 1987; 155: 1260-1265.
31. Robbins JB, Schneerson R, Szu SC. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis 1995; 171: 1387-1398.
32. Sansonetti PJ, Phalipon A, Arondel J, Thirumalai K, Banerjee S, Akira S, et al. Caspase-activation of IL-1beta and IL-18 are essential for Shigella flexneri-induced inflammation. Immunity 2000; 12: 581-590.
33. Pickett TE, Pasetti MF, Galen JE, Sztein MB, Levine MM. In vivo characterization of the murine intranasal model for assessing the immunogenicity of attenuated Salmonella enterica serovar Typhi strains as live mucosal vaccines and as live vectors. Infect Immun 2000; 68: 205-213.
34. Southam DS, Dolovich M, O'Byrne PM, Inman MD. Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesia. Am J Physiol Lung Cell Mol Physiol 2002; 282: L833-L839.
35. Lewis DJ, Huo Z, Barnett S, Kromann I, Giemza R, Galiza E, et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS ONE 2009; 4: e6999.
36. Qadri F, Bhuiyan TR, Sack DA, Svennerholm AM. Immune responses and protection in children in developing countries induced by oral vaccines. Vaccine 2013; 31: 452-460.
37. Mallett CP, Hale TL, Kaminski RW, Larsen T, Orr N, Cohen D, et al. Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection. Infect Immun 1995; 63: 2382-2386.
38. Orr N, Robin G, Cohen D, Arnon R, Lowell GH. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models. Infect Immun 1993; 61: 2390-2395.
39. Mitra S, Barman S, Nag D, Sinha R, Saha DR, Koley H. Outer membrane vesicles of Shigella boydii type 4 induce passive immunity in neonatal mice. FEMS Immunol Med Microbiol 2012; 66: 240-250.
40. Mitra S, Chakrabarti MK, Koley H. Multi-serotype outer membrane vesicles of Shigellae confer passive protection to the neonatal mice against shigellosis. Vaccine 2013; 31: 3163-3173.
41. Jeong KI, Venkatesan MM, Barnoy S, Tzipori S. Evaluation of virulent and live Shigella sonnei vaccine candidates in a gnotobiotic piglet model. Vaccine 2013; 31: 4039-4046.
42. Choudhari SP, Kramer R, Barta ML, Greenwood JC, Geisbrecht BV, Joshi SB, et al. Studies of the conformational stability of invasion plasmid antigen B from Shigella. Protein Sci 2013; 22: 666-670.
43. Choudhari SP, Chen X, Kim JH, van Roosmalen ML, Greenwood JC, Joshi SB, et al. Biophysical characterization of the type III secretion tip proteins and the tip proteins attached to bacterium-like particles. J Pharm Sci 2014; 104: 424-432.
44. Birket SE, Harrington AT, Espina M, Smith ND, Terry CM, Darboe N, et al. Preparation and characterization of translocator/chaperone complexes and their component proteins from Shigella flexneri. Biochemistry 2007; 46: 8128-8137.
45. Simon R, Tennant SM, Wang JY, Schmidlein PJ, Lees A, Ernst RK, et al. Salmonella enterica serovar enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidis. Infect Immun 2011; 79: 4240-4249.
46. Zychlinsky A, Prevost MC, Sansonetti PJ. Shigella flexneri induces apoptosis in infected macrophages. Nature 1992; 358: 167-169.
47. Zauberman A, Cohen S, Levy Y, Halperin G, Lazar S, Velan B, et al. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague. Vaccine 2008; 26: 1616-1625.
48. Hilbi H, Puro RJ, Zychlinsky A. Tripeptidyl peptidase II promotes maturation of caspase-1 in Shigella flexneri-induced macrophage apoptosis. Infect Immun 2000; 68: 5502-5508.
49. Zychlinsky A, Kenny B, Menard R, Prevost MC, Holland IB, Sansonetti PJ. IpaB mediates macrophage apoptosis induced by Shigella flexneri. Mol Microbiol 1994; 11: 619-627.